Key facts
- This page summarizes Janet S. Vergis's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 09 Jun 2025, 16:25.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Award
Additional SEC filing notes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Footnote F3
Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.
Footnote F4
Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.